K. Kobayashi

发表

Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study

P. Jänne, D. Planchard, S. Kim, 2021, ESMO open.

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial

C. Ishioka, H. Shimodaira, S. Morita, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I/II trial of a biweekly combination of S-1 plus docetaxel in patients with previously treated non-small cell lung cancer (KRSG-0601)

N. Takayanagi, K. Mori, A. Sutani, 2012, British Journal of Cancer.

First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: A phase III study (002) by North East Japan Gefitinib Study Group.

A. Gemma, Kunihiko Kobayashi, S. Oizumi, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).

A. Gemma, S. Morita, Kunihiko Kobayashi, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of gefitinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) gene mutations detected by PNA-LNA PCR clamp.

K. Hagiwara, H. Miyazawa, A. Sutani, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp

K. Hagiwara, M. Kanazawa, H. Miyazawa, 2006, British Journal of Cancer.

Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study

Y. Nasu, K. Mikami, J. Furukawa, 2020, Japanese journal of clinical oncology.

Individualizing dosing of cancer chemotherapy.

M. Ratain, K. Kobayashi, 1993, Seminars in oncology.

Standard steroid treatment for autoimmune pancreatitis

T. Shimosegawa, M. Omata, K. Okazaki, 2009, Gut.

DNA hypermethylation at the D17S5 locus in non-small cell lung cancers: its association with smoking history.

S. Hirohashi, Y. Kanai, K. Kobayashi, 1997, Cancer research.

Prediction of anti-tumour effect of thermochemotherapy with in vitro thermochemosensitivity testing for non-small cell lung cancer

T. Abiko, Y. Saito, M. Kawamura, 2007, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

Long-term follow-up study of ulcerative colitis in Japan.

A. Terano, H. Watanabe, T. Muto, 1995, Journal of gastroenterology.

Evaluation of neuropathy in patients on suramin treatment

M. Ratain, E. Vokes, B. Soliven, 1997, Muscle & nerve.

Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.

L Janish, M J Ratain, M. Ratain, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring.

M. Ratain, D. Jodrell, K. Kobayashi, 1993, Cancer surveys.

Suramin: is adaptive control necessary?

M. Ratain, E. Vokes, N. Vogelzang, 1992, Journal of Clinical Oncology.

Simultaneous occurrence of anti‐BP180 mucous membrane pemphigoid and mucosal‐dominant pemphigus vulgaris

T. Hashimoto, S. Nakajima, K. Kobayashi, 2009, Clinical and experimental dermatology.

A phase I study of intermittent infusion cladribine in patients with solid tumors

R. Schilsky, M. Ratain, E. Vokes, 1994, Cancer.

Randomized phase II study of concurrent versus sequential alternating ge fi tinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations : NEJ 005 / TCOG 0902

A. Gemma, S. Morita, M. Kurihara, 2015 .

A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial

A. Gemma, S. Kudoh, H. Ohmatsu, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.

A. Gemma, S. Morita, M. Kurihara, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Therapeutic efficacy of cyclic home elemental enteral alimentation in Crohn's disease: Japanese cooperative Crohn's disease study.

A. Terano, K. Matsueda, T. Bamba, 1995, Journal of gastroenterology.

The BRAAFF checklist: a new dermoscopic algorithm for diagnosing acral melanoma

H. Koga, A. Lallas, I. Zalaudek, 2015, The British journal of dermatology.

Keratoacanthomas and skin neoplasms associated with suramin therapy.

E. Vokes, N. Vogelzang, K. Soltani, 1996, Archives of dermatology.

Entire hemithorax irradiation following complete resection in patients with stage II-III invasive thymoma.

J. Itami, M. Uematsu, M. Kondo, 1996, International journal of radiation oncology, biology, physics.

Clinical evaluation of teprenone, a mucosal protective agent, in the treatment of patients with gastric ulcers: a nationwide, multicenter clinical study.

T. Takemoto, K. Ogoshi, K. Nakamura, 1995, Clinical therapeutics.

Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.

A. Gemma, Kunihiko Kobayashi, S. Oizumi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G).

Y. Ichinose, H. Saka, K. Kiura, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New perspectives on the toxicity of etoposide.

M. Ratain, K. Kobayashi, 1992, Seminars in oncology.

A cross-validation of the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer.

H Sakai, H. Ogasawara, S. Teramukai, 1998, European journal of cancer.

9LBA A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study

S. Morita, S. Oizumi, M. Maemondo, 2009 .

CD66c (KOR‐SA3544) antigen expression of leukemic blasts in pediatric acute myeloid leukemia with TLS/FUS‐ERG fusion transcript

H. Kawaguchi, M. Kawamura, K. Kobayashi, 2017, International journal of laboratory hematology.

Simultaneous occurrence of anti‐BP180 mucous membrane pemphigoid and mucosal‐dominant pemphigus vulgaris

S. Nakajima, K. Kobayashi, T. Harada, 2009, Clinical and experimental dermatology.